Market closed

CRISPR/$CRSP

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About CRISPR

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Ticker

$CRSP
Trading on

Industry

Biotechnology

Headquarters

Zug, Switzerland

Employees

407

CRISPR Metrics

BasicAdvanced
$4B
Market cap
-
P/E ratio
-$2.90
EPS
1.66
Beta
-
Dividend rate
$4B
1.66
$91.10
$43.42
1.6M
21.644
21.553
10.861
11.731
-9.57%
-13.07%
19.319
2.08
2.08
-20.494
19.31%
-35.36%
-39.20%
-18.04%

What the Analysts think about CRISPR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for CRISPR stock.

CRISPR Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CRISPR Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CRSP

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for CRISPR stock?

CRISPR (CRSP) has a market cap of $4B as of November 22, 2024.

What is the P/E ratio for CRISPR stock?

The price to earnings (P/E) ratio for CRISPR (CRSP) stock is 0 as of November 22, 2024.

Does CRISPR stock pay dividends?

No, CRISPR (CRSP) stock does not pay dividends to its shareholders as of November 22, 2024.

When is the next CRISPR dividend payment date?

CRISPR (CRSP) stock does not pay dividends to its shareholders.

What is the beta indicator for CRISPR?

CRISPR (CRSP) has a beta rating of 1.66. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.